Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Genetic Testing Market Size & Growth Forecast 2027–2036, By Segments (Products & Services, Techniques, Test Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 6967| Published Date: Jul-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Genetic Testing Market size was over USD 25.07 Billion in 2026 and is likely to grow at 12.79% CAGR between 2027 and 2036, attaining USD 83.53 Billion by 2036. The industry revenue for 2027 is calculated at USD 27.85 Billion.

Base Year Value (2025)
USD 22.87 Billion
CAGR (2026-2035)
12.3%
Forecast Year Value (2035)
USD 72.96 Billion
Historical Data Period
2021-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Genetic Testing Market Intelligence Snapshot

Regional Market Dynamics

Segment Momentum

Market Expansion Drivers

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Regional and Segment Outlook

MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Increasing adoption of personalized medicine driving genetic diagnostics demand

Healthcare providers are increasingly adopting personalized treatment approaches that rely on genetic insights to guide clinical decision-making, a trend that will propel the genetic testing market growth. Genetic diagnostics help identify inherited variations, predict disease susceptibility, and support the selection of therapies tailored to individual patient profiles. As precision medicine becomes more integrated into routine healthcare, demand continues to expand for genetic testing across preventive care, diagnosis, treatment planning, and long-term disease management.

Expanding oncology and rare disease applications accelerating clinical genetic testing usage

The expanding role of genetic analysis in oncology and rare disease diagnosis is creating broader clinical demand, making the genetic testing market a critical component of modern healthcare. Genetic testing enables clinicians to identify disease-associated mutations, confirm complex diagnoses, and support the development of targeted treatment strategies for patients with specific genetic characteristics. Improved understanding of genomic variations is also enhancing patient stratification and facilitating more informed therapeutic decisions across specialized medical settings.

Growing direct-to-consumer genetic testing expanding consumer-driven genomics adoption

Rising consumer interest in personal health information is encouraging wider adoption of direct-to-consumer genetic testing services, which will boost the genetic testing market demand. These services provide individuals with accessible insights into ancestry, inherited traits, wellness indicators, and selected genetic risk factors without requiring traditional clinical pathways. Greater awareness of preventive healthcare and advances in digital health platforms are supporting stronger consumer engagement with genomics while expanding participation beyond conventional healthcare environments.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Increasing adoption of personalized medicine driving genetic diagnostics demand 2.2% High North America, Europe High Near Term
Expanding oncology and rare disease applications accelerating clinical genetic testing usage 2% High North America, Asia Pacific High Mid Term
Growing direct-to-consumer genetic testing expanding consumer-driven genomics adoption 1.8% Moderate North America, Europe High Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
49.08% Market Share in 2026

North America (Largest Region)

North America accounted for the largest share of the genetic testing market, representing 49.08% in 2026, supported by advanced healthcare infrastructure, broad availability of molecular diagnostic technologies, and growing integration of genetic information into clinical decision-making. Increasing awareness of inherited disorders and the role of genetic testing in disease risk assessment, diagnosis, and treatment selection is strengthening demand. The region also benefits from established research capabilities and continued investment in precision medicine, which are encouraging the adoption of increasingly sophisticated testing approaches across clinical and healthcare settings.

Asia Pacific (Fastest-Growing Region)

Asia Pacific is expected to register the fastest growth, driven by rising healthcare expenditure, improving diagnostic infrastructure, and increasing awareness of genetic diseases and personalized medicine. Expanding access to advanced molecular testing is enabling healthcare providers to incorporate genetic information into disease diagnosis and treatment planning. In addition, growing research activity, improving laboratory capabilities, and increasing demand for early and more precise disease detection are creating opportunities for genetic testing adoption across the region.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

United States 🇺🇸

Precision Diagnostics Expansion

The U.S. genetic testing market is advancing through broader adoption of precision medicine, hereditary disease screening, and oncology diagnostics. Healthcare providers and testing companies continue improving genomic interpretation capabilities while expanding access through integrated clinical workflows and digital health platforms.

Germany 🇩🇪

Clinical Genomics Integration

Germany is strengthening the genetic testing market by integrating genomic diagnostics into specialized healthcare and research networks. Laboratories emphasize high-quality testing standards, molecular diagnostics, and collaboration with healthcare providers to support personalized treatment planning and disease prevention initiatives.

Japan 🇯🇵

Preventive Genomic Applications

Japan is expanding the use of genetic testing across preventive healthcare, rare disease diagnosis, and oncology. The market prioritizes reliable laboratory services, efficient diagnostic workflows, and technological innovation that enhances clinical decision-making while supporting an aging population.

South Korea 🇰🇷

Digital Genomics Innovation

South Korea is combining advanced biotechnology capabilities with digital healthcare infrastructure to strengthen genetic testing services. Companies focus on next-generation sequencing, AI-assisted genomic analysis, and consumer health applications that improve testing accessibility and clinical efficiency.

France 🇫🇷

Personalized Care Support

France continues to integrate genetic testing into personalized healthcare through expanding molecular diagnostics and specialized clinical programs. The market emphasizes quality assurance, evidence-based applications, and stronger collaboration between healthcare institutions and genomic research organizations.

Italy 🇮🇹

Specialized Diagnostic Networks

Italy is reinforcing genetic testing through specialized diagnostic centers and increasing adoption of molecular medicine. Healthcare providers prioritize early disease identification, hereditary condition screening, and laboratory modernization to improve diagnostic accuracy across multiple therapeutic areas.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Genetic Testing Market Share (%), Products & Services, 2025

Kits & Reagents
Kits & reagents

Go beyond the chart, access full insights & data tables

Request Free Sample Report

Products & Services Segment Analysis: Kits & Reagents (Largest Segment) vs Software & Services (Fastest-Growing Segment)

In the genetic testing market, the kits & reagents segment held the largest share of 62.5% in 2026. Its leading position is supported by the routine and repeated consumption of reagents across diagnostic laboratories, research institutions, and clinical testing facilities. The expanding use of genetic analysis in disease detection, inherited disorder screening, and precision medicine continues to drive consistent demand for high-quality consumables, making kits and reagents an essential component of testing workflows.

The software & services segment is expected to register the fastest growth as genetic testing generates increasingly complex datasets that require advanced interpretation and efficient data management. Greater reliance on bioinformatics platforms, automated analysis tools, and specialized interpretation services is strengthening demand for software-driven solutions. The growing emphasis on integrating genomic information into clinical decision-making and improving laboratory efficiency further supports the expansion of this segment.

Techniques Segment Analysis: DNA Sequencing (Largest & Fastest-Growing Segment)

Holding the largest share of the genetic testing market, the DNA sequencing segment accounted for 44.1% in 2026 while also emerging as the fastest-growing technique. Its leadership is driven by its ability to provide comprehensive genetic information with high accuracy across a broad range of clinical and research applications. Continuous improvements in sequencing technologies, increasing adoption in personalized medicine, and expanding use in disease diagnosis, inherited disorder analysis, and oncology have strengthened its market position. Growing investments in genomic research and the need for detailed molecular insights are expected to further reinforce the adoption of DNA sequencing across healthcare and life science applications.

Test Type Segment Analysis: Prenatal and Newborn Testing (Largest Segment) vs Carrier Testing (Fastest-Growing Segment)

The prenatal and newborn testing segment dominated with a market share of 42.77% in 2026 due to the increasing emphasis on early identification of genetic abnormalities and inherited disorders. Widespread implementation of newborn screening programs and growing awareness regarding preventive healthcare have encouraged broader adoption of these tests. Healthcare providers are also placing greater importance on early intervention strategies that improve long-term patient outcomes.

Carrier testing is anticipated to witness the fastest growth in the genetic testing market as awareness of inherited disease risks continues to increase among prospective parents and families with a history of genetic disorders. Rising utilization of genetic counseling and proactive reproductive planning has expanded the demand for carrier screening. Advancements in testing technologies and broader accessibility of genetic services are further supporting the rapid adoption of carrier testing.

Segment Sub-Segment Largest Segment Fastest Growing
Products & Services Kits & reagents, Software & services
Test Type Predictive testing, Carrier testing, Prenatal and newborn testing, Diagnostic testing, Pharmacogenomic testing, Nutrigenomics, Other test types
Application Cancer treatment, Tissue typing for transplantation, Forensic identity testing, Ancestry testing, Paternity testing, Other applications
Techniques Polymerase chain reaction, DNA sequencing, Cytogenetic testing, Microarrays, Gene expression profiling
End-use Hospitals & clinics, Diagnostic laboratories, Forensic laboratories, Other end-users
Competitive Landscape

Competitive Landscape and Market Positioning

Prominent players in the genetic testing market:

  1. Illumina, Inc. (United States)
  2. Thermo Fisher Scientific, Inc. (United States)
  3. QIAGEN N.V. (Netherlands)
  4. Quest Diagnostics Incorporated (United States)
  5. Natera, Inc. (United States)
  6. Myriad Genetics, Inc. (United States)
  7. BGI Genomics Co., Ltd. (China)
  8. 23andMe Holding Co. (United States)
  9. Siemens Healthineers AG (Germany)
  10. Abbott Laboratories (United States)

Scientific innovation and expanding clinical adoption continue to redefine competitive dynamics in the Genetic Testing Market, with differentiation increasingly emerging from testing accuracy, interpretation capabilities, and the breadth of diagnostic applications. Market participants are strengthening their positions through improvements in sequencing technologies, bioinformatics platforms, and integrated data analysis that enable more actionable clinical insights across preventive care, disease diagnosis, and personalized medicine. Competition is also extending beyond laboratory performance toward workflow efficiency, regulatory compliance, and the ability to support healthcare providers with scalable testing services. Growing emphasis on data privacy, clinical validation, and standardized reporting further elevates the importance of trusted diagnostic platforms capable of meeting evolving healthcare requirements across multiple care settings.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Vitalant Jun-26 Vitalant expanded its next-generation sequencing infrastructure at its Pittsburgh laboratory, linking it with Phoenix and San Francisco sites into a hub-and-spoke production network. The expansion scales analytical capacity for cell therapy development and bleeding disorder diagnostics.
Labcorp Apr-26 Labcorp partnered with the Children's Hospital of Philadelphia to accelerate the development and commercialization of pediatric specialty diagnostics, directly expanding hospital access to advanced pediatric genetic testing panels.
PrecisionLife Apr-26 PrecisionLife partnered with Ovation.io to commercialize direct-to-consumer and laboratory-developed genetic tests. The diagnostic panels predict individual patient efficacy and response variations to GLP-1 therapies, extending precision medicine applications.
SumHealth Sep-25 SumHealth partnered with Nucleus Genomics to integrate clinical-grade whole-genome DNA testing across commercial hospitals, pharmacies, and regional health systems, expanding the institutional distribution network for comprehensive genomic testing.
VieCure Jul-25 VieCure partnered with Guardant Health to integrate liquid biopsy and solid tissue genomic testing data into AI-powered oncology workflows, building real-time clinical decision support loops for decentralized community oncology practices.
QIAGEN May-25 QIAGEN acquired Israeli AI genomics developer Genoox for approximately US$80 million. The transaction integrates Genoox's Franklin platform into QIAGEN's portfolio, expanding its clinical genetic testing footprint with advanced, AI-powered genomic interpretation software capabilities.
GeneDx Apr-25 GeneDx acquired Fabric Genomics to merge its clinical laboratory infrastructure with Fabric's AI-driven variant prioritization software. The acquisition scales its clinical genetic testing throughput and accelerates turnaround times for rare disease diagnostics.
Labcorp Aug-24 Labcorp acquired select genetic testing assets and technology infrastructure from Invitae. The transaction directly expands Labcorp's personalized medicine market share, strengthening its commercial oncology and reproductive health diagnostic portfolios.
Baylor Genetics Aug-24 Baylor Genetics and Baylor College of Medicine co-launched the Medical Genetics Multi-Omics Laboratory. The new facility expands specialized clinical capacity, uniting routine genetic testing workflows with high-throughput multi-omics research.
Sysmex Corporation Feb-24 Sysmex Corporation and Hitachi High-Tech Corporation entered a strategic development partnership to engineer advanced genetic testing systems using capillary electrophoresis sequencers. The alignment aims to scale manufacturing and enter untapped international markets.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Genetic Testing Market — Custom Segments

Segment Sub-Segment
No segment data available.

Genetic Testing Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

How much is the genetic testing market worth?

The market size of genetic testing in 2026 is calculated to be USD 25.39 billion.

How is the genetic testing industry projected to perform over the next decade?

Genetic Testing Market size is set to grow from USD 22.87 billion in 2025 to USD 72.96 billion by 2035, reflecting a CAGR greater than 12.3% through 2026-2035.

What is the leading region in terms of genetic testing industry share?

North America region held around 43.3% market share in 2025, driven by advanced diagnostics and personalized medicine drive share.

Which region is experiencing the fastest growth in the genetic testing sector?

Asia Pacific region will record over 14.5% CAGR between 2026 and 2035, led by growing healthcare and genetic research fuel growth.

Why does kits & reagents sub-segment dominate the products & services segment of genetic testing sector?

The kits & reagents segment will hold 63.7% genetic testing market share in 2025, led by widespread use in diagnostic and research applications.

How does diagnostic laboratories sub-segment fare in the genetic testing industry?

Securing 49.5% of the market in 2025, diagnostic laboratories segment was strengthened by centralized testing facilities for high-throughput analysis.

What share does DNA sequencing hold in the genetic testing sector as of 2025?

The DNA sequencing segment recorded 39.52% revenue share in 2025, impelled by broad application in clinical and research settings.

What are the key competitors in the genetic testing landscape?

Top companies in the genetic testing market comprise Illumina (USA), Thermo Fisher (USA), Quest Diagnostics (USA), Myriad Genetics (USA), Invitae (USA), Eurofins (France), BGI Genomics (China), LabCorp (USA), Ambry Genetics (USA), Natera (USA).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →